

LECTURE

Khalid Shah, MS, PhD

Director, Center for Stem Cell Therapeutics and Imaging
Harvard Medical School

Vice Chairman, Department of Neurosurgery, Brigham and
Women's Hospital

**RECEPTOR TARGETED ENGINEERED STEM
CELLS: THERAPEUTIC APPLICATION FOR
CANCER AND BEYOND.**

Location: Room 5.29, 5B3, University Hospital Ghent.

When? October 19th, 2018 at 3 PM.

Contact

Prof. Jan Gettemans, Dept. Biochemistry (Jan.Gettemans@ugent.be) Tel: 092649340

Biography



Dr. Shah is an Associate Professor at Harvard Medical School and the Director of the Center for Stem Cell Therapeutics and Imaging at Brigham and Women's Hospital (BWH). He is also the Vice Chair of Research for the Department of Neurosurgery at BWH and a Principal Faculty at Harvard Stem Cell Institute in Boston. Since his move to BWH, he has started a joint Center of Excellence in Biomedicine with KACST and is also directing the new Center.

Dr. Shah and his team have pioneered major developments in the stem cell therapy field, successfully developing experimental models to understand basic cancer biology and therapeutic stem cells for cancer. These studies have been published in a number of very high impact journals like *Nature Neuroscience*, *PNAS*, *Nature Reviews Cancer*, *JNCI*, *Stem Cells* and *Lancet Oncology*. Previously, Dr. Shah's stem cell work has caught the attention in the public domain and as such it has been highlighted in the media world-wide including features on BBC and CNN. Recently, Dr. Shah's laboratory has reverse engineered cancer cells using CRISPR/Cas9 technology and utilized them as therapeutics to treat cancer. This work was published in journal *Science Translation Medicine* and highlighted world-wide including features on Scientific American, New York Times and Fox news. Dr. Shah holds current positions on numerous councils, advisory and editorial boards in the fields of stem cell therapy and oncology. In an effort to translate the exciting therapies developed in his laboratory into clinics, he has recently founded biotech company, AMASA Technologies Inc. whose main objective is the clinical translation of therapeutic stem cells in cancer patients.